Wyndly Analysis: $2M Raised
What is Wyndly?
Wyndly offers personalized sublingual immunotherapy for allergy sufferers, enabling them to retrain their immune systems at home without allergy shots.
Employees
10
Founded
2020
Revenue
$0-5M
Company Stage
Seed
YC Batch
W21
Product Features & Capabilities
- personalized sublingual immunotherapy treatment plans, no allergy shots required, FDA-approved sublingual tablets, dedicated board-certified doctor support, medication delivered to your doorstep, allergy testing for 40+ allergens, money-back guarantee if no relief in three months
How much Wyndly raised
1 - $2 million
January 15, 2025Lead Investor: Y Combinator, Goodwater Capital
Who are the founders of Wyndly
AS
Aakash Shah
CEO
MS
Manan Shah
Chief Medical Officer
Company Pricing
- $100 per month for treatment subscription
- 6-month membership: $600
- Annual membership: $1100 (savings of $100)
- One-time fee for allergy testing: $99
- Unlimited doctor visits and medications included in membership
Investors
- Y Combinator
- Goodwater Capital
- Civilization Ventures
- Sweater Ventures
- Kevin Mahaffey
- Cashmere Fund
- Immeasurable
- Underdog Labs
